European Commission logo
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-05-27

The second phase of a european malaria vaccine development consortium

Objective

The EUROMALVAC2 consortium will develop malaria vaccines inducing protective antibody responses to P.falciparum bloodstage antigens, moving leading vaccine candidates towards GMP-production and clinical trial whilst validating 2nd and 3rd generation candidates in its malaria vaccine R&D 'pipeline '. The major projects within the EUROMALVAC2 work programme involve; a. Optimisation of synthesis of lead candidate malaria vaccines based on merozoite surface protein 1 (MSPl) and the apical merozoite antigen 1 (AMAl). b. Production and testing of more parasitised erythrocyte membrane protein (PfEMP-l) based vaccines. c. Production and testing of new vaccine formulations based on the N-terminal Block 2 sequences of MSP1 and on other, less well characterised merozoite antigens. d. Development of a transmission blocking vaccine based on gametocyte antigen Pfs48/45. e. Strengthening of preclinical and clinical testing facilities.

Call for proposal

Data not available

Coordinator

UNIVERSITY OF EDINBURGH
EU contribution
No data
Address
West Mains Road, Ashworth Laboratories, King's Bu
EH9 3JT EDINBURGH
United Kingdom

See on map

Total cost
No data

Participants (11)